公开(公告)号：US08802690B2

公开(公告)日：2014-08-12

申请号：US13939450

申请日：2013-07-11

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  David Andrew Griffith ,  Daniel Wei-Shung Kung

IPC: C07D487/10 ,  A61K31/438

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

公开(公告)号：US20240391908A1

公开(公告)日：2024-11-28

申请号：US18789977

申请日：2024-07-31

Applicant: Pfizer Inc.

Inventor： Andrew John Bessire ,  David James Edmonds ,  David Andrew Griffith ,  Amit Sumant Kalgutkar ,  Timothy Frank Ryder

IPC: C07D405/14 ,  A61K45/06 ,  C07D401/14

Abstract: The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.

公开(公告)号：US20210047325A1

公开(公告)日：2021-02-18

申请号：US17034295

申请日：2020-09-28

Applicant: Pfizer Inc.

Inventor： Mary Theresa Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: C07D471/10 ,  C07D491/20 ,  C07D519/00 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  A61K31/435

Abstract: The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

公开(公告)号：US09145416B2

公开(公告)日：2015-09-29

申请号：US14491016

申请日：2014-09-19

Applicant: Pfizer Inc.

Inventor： Mary Theresa Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: A61K31/44 ,  C07D471/10 ,  C07D491/20 ,  C07D519/00 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  A61K31/435

CPC classification number: C07D471/10 ,  A61K31/435 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R1，R2，R3，Z，A1，L和A2如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

公开(公告)号：US08507681B2

公开(公告)日：2013-08-13

申请号：US13644415

申请日：2012-10-04

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  David Andrew Griffith ,  Daniel Wei-Shung Kung

IPC: C07D401/04 ,  C07D401/14 ,  A61K31/438

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

公开(公告)号：US20230322777A1

公开(公告)日：2023-10-12

申请号：US18311715

申请日：2023-05-03

Applicant: Pfizer Inc.

Inventor： Mary Theresa Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: C07D471/10 ,  A61K31/435 ,  A61K31/519 ,  C07D519/00 ,  C07D487/10 ,  C07D491/20 ,  A61K45/06 ,  A61K31/438

CPC classification number: C07D471/10 ,  A61K31/435 ,  A61K31/519 ,  C07D519/00 ,  C07D487/10 ,  C07D491/20 ,  A61K45/06 ,  A61K31/438

Abstract: The invention provides a compound of Formula (I)




or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

公开(公告)号：US20220387402A1

公开(公告)日：2022-12-08

申请号：US17612672

申请日：2020-05-15

Applicant: Pfizer Inc.

Inventor： Gary E. Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew Dowling ,  David James Edmonds ,  Dilinie Fernando ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David Andrew Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Shawn M. LaCasse ,  Yajing Lian ,  Chris Limberakis ,  Allyn T. Londregan ,  Alan M. Mathiowetz ,  David Walter Piotrowski ,  Roger B. Ruggeri ,  Kristin Wiglesworth

IPC: A61K31/438 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/46 ,  A61K45/06 ,  A61K38/26 ,  A61K38/28 ,  A61K38/17 ,  A61P1/16

Abstract: In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

公开(公告)号：US20190218218A1

公开(公告)日：2019-07-18

申请号：US16371896

申请日：2019-04-01

Applicant: Pfizer Inc.

Inventor： Mary Theresa Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: C07D471/10 ,  C07D487/10 ,  A61K45/06 ,  C07D519/00 ,  A61K31/438 ,  A61K31/435 ,  A61K31/519 ,  C07D491/20

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use to thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

公开(公告)号：US09908883B2

公开(公告)日：2018-03-06

申请号：US15236635

申请日：2016-08-15

Applicant: PFIZER INC.

Inventor： Mary Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: A61K31/44 ,  C07D471/10 ,  C07D491/20 ,  C07D519/00 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  A61K31/435

CPC classification number: C07D471/10 ,  A61K31/435 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

公开(公告)号：US20150376185A1

公开(公告)日：2015-12-31

申请号：US14851572

申请日：2015-09-11

Applicant: PFIZER INC.

Inventor： Mary Theresa Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: C07D471/10 ,  A61K31/435 ,  A61K45/06

CPC classification number: C07D471/10 ,  A61K31/435 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.